Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

254.28
+5.582.24%
Post-market: 254.280.00000.00%19:52 EDT
Volume:516.75K
Turnover:131.04M
Market Cap:16.51B
PE:17.38
High:255.85
Open:248.75
Low:248.55
Close:248.70
52wk High:265.05
52wk Low:121.40
Shares:64.91M
Float Shares:62.69M
Volume Ratio:1.04
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.44
PE(LYR):-43.54

Loading ...

Jazz director Heather Ann McSharry disposes of Jazz Pharma shares worth $482,000

Reuters
·
May 28

Jazz Pharmaceuticals Phase 3 HERIZON-GEA-01 results published in NEJM

TIPRANKS
·
May 28

Jazz Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
May 28

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Barclays

TIPRANKS
·
May 27

CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

TIPRANKS
·
May 23

Jazz Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 22

Bernstein Initiates Coverage on Jazz Pharmaceuticals With Market Perform Rating

MT Newswires Live
·
May 22

U.S. RESEARCH ROUNDUP-Jazz Pharmaceuticals, Target, Workday

Reuters
·
May 22

Jazz Pharmaceuticals Plc : Piper Sandler Raises Target Price to $301 From $232

THOMSON REUTERS
·
May 22

Bernstein starts Jazz at Market Perform, says clock ticking on blockbuster drugs

TIPRANKS
·
May 22

J.P. Morgan Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
May 20

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Jazz Pharmaceuticals Plc : JP Morgan Resumes Coverage With Overweight Rating; Price Target $265

THOMSON REUTERS
·
May 20

Jazz Pharmaceuticals Raised to Buy From Neutral by UBS

Dow Jones
·
May 19

UBS Revises Jazz Pharmaceuticals Outlook, Citing Strong Core Business and Promising Oncology Drug

Deep News
·
May 19

Lifeward names Keith D. Rose chief medical officer

Reuters
·
May 19

Jazz Pharmaceuticals Plc : UBS Raises to Buy From Neutral

THOMSON REUTERS
·
May 19

Jazz Pharmaceuticals upgraded to Buy from Neutral at UBS

TIPRANKS
·
May 19

Jazz Pharma joins RBC Global Healthcare Conference fireside chat

Reuters
·
May 13

Werewolf Therapeutics Q1 net loss narrows to $13.5 million; R&D expenses drop to $8.2 million

Reuters
·
May 08